Glutathione Reductase Expression and Its Prognostic Significance in Colon Cancer

Area of Science:

• Biochemistry
• Oncology
• Cell Biology

Background:

• Cellular redox balance is vital for life, maintained by antioxidant pathways like the glutathione (GSH)/glutaredoxin (Grx) system.
• Glutathione reductase (GR) catalyzes GSH disulfide reduction, ensuring a supply of reduced GSH, a key antioxidant.
• Dysregulation of cellular antioxidants, including GR, may influence cancer development.

Purpose of the Study:

• To investigate the relationship between GR protein expression and colon adenocarcinoma.
• To determine if GR expression levels correlate with tumor stage, grade, and other prognostic factors.

Main Methods:

• Immunohistochemical analysis of GR protein expression in colon adenocarcinoma patient samples (Stages I-III).
• Correlation analysis between GR expression and clinicopathological features (histological grade, invasion depth, lymph node involvement, staging).
• Western blot analysis of GR expression in the LS 174T cell line.

Main Results:

• A significant association was found between GR expression and tumor grade, invasion depth, lymph node status, and staging.
• 95% of Stage I patients showed low GR expression, while 89% of Stage III patients exhibited high GR expression.
• 63% of Stage II patients also displayed high GR expression, with the LS 174T cell line (Stage II) showing the highest expression via Western blot.

Conclusions:

• Immunohistochemical expression of GR is significantly related to various clinicopathological features of colon adenocarcinoma.
• GR expression levels increase with tumor stage, indicating a potential role in cancer progression.
• GR may serve as an independent prognostic factor for colon adenocarcinoma patients.